Literature DB >> 16334157

Tumour control probability of stage III inoperable non-small cell lung tumours after sequential chemo-radiotherapy.

S Y El Sharouni1, H B Kal, J J Battermann.   

Abstract

UNLABELLED: The aim of this study was to investigate the influence of the duration of waiting time between the end of induction chemotherapy and the start of radiotherapy on tumour control probability (TCP). PATIENTS AND METHODS: Twenty-three patients with inoperable stage III non-small cell lung cancer (NSCLC) received induction chemotherapy followed by radiotherapy. The mean waiting period between the end of induction chemotherapy and the start of radiotherapy was 80 days; in this period, the median tumour volume increased by a factor of about 6. The Poisson model for TCP and the linear-quadratic model were used to calculate changes in TCP in the waiting time.
RESULTS: The 2-year survival of patients treated with curative intent was 8%, lower than the mean value of 26% derived from other studies. Assuming that radiotherapy started on the day of restaging or on the first day of radiotherapy (RT1), the calculated mean TCP at restaging was 13.3% and at RT1 was 0.5% for patients treated with curative intent.
CONCLUSION: The calculated TCP decreased in the waiting period from 13.3 to less than 1%. Hence, the relatively long interval time between chemo- and radiotherapy had a deleterious effect on local control. We recommend the waiting time to be as short as possible.

Entities:  

Mesh:

Year:  2005        PMID: 16334157

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Preclinical and pilot clinical studies of docetaxel chemoradiation for Stage III non-small-cell lung cancer.

Authors:  Yuhchyau Chen; Kishan J Pandya; Ollivier Hyrien; Peter C Keng; Therese Smudzin; Joy Anderson; Raman Qazi; Brian Smith; Thomas J Watson; Richard H Feins; David W Johnstone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-12       Impact factor: 7.038

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.